Clinical Trial Update: Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma [Phase 1]

View source ↗

Summary

Phase 1 safety and efficacy study update for combining BMS-908662 with ipilimumab in subjects with advanced melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BMS-908662
• ipilimumab (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 1 | Status: COMPLETED